In this article, we will be looking at 11 best long term low risk stocks to buy.
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment. The Federal Reserve has been holding interest rates steady at 4.25% to 4.5% through 2025. With a potential cut anticipated in September, investors are reconstructing their expectations around monetary policy, inflation resilience, and political noise from Washington.
Forbes reports that although inflation has eased and employment remains solid, President Trump has made sharp criticism of Fed Chair Jerome Powell, adding an unusual layer of pressure to an otherwise technical process handled by experts. These tensions matter because interest rate decisions affect discount rates and the relevance of dividend yields, as well as investors’ preferences for stable long-term holdings.
Long-term low-risk stocks appear attractive, especially in an environment like this. Their appeal is backed by many equities that have historically offered consistent returns to investors through thick and thin. In this article, we have brought to you 11 best long term low risk stocks that offer stability to your investments.
Let’s count them down from 11 to 1 and see how many would make it to your portfolio.
TZIDO SUN/Shutterstock.com
Our Methodology
When putting together our list of 11 best long term low risk stocks to buy, we followed a few criteria. Primarily, we did not include any stock with a beta of more than 0.5, thus ensuring low risk in all the stocks on our list. Similarly, to ensure growth in the long term, we have included only those stocks with a positive Earnings Per Share (EPS) growth for the next 5 years. Also, all the stocks on our list have a strong Buy rating. The companies are ranked based on EPS growth for the next 5 years.
All the data used in the article was taken from financial databases and analyst reports, with all information updated as of July 22, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11. A-Mark Precious Metals, Inc. (NASDAQ:AMRK)
EPS next 5Y: 3.40%
Beta: 0.15
A-Mark Precious Metals, Inc. (NASDAQ:AMRK) holds a place among our list of 11 best long term low risk stocks to buy. Analysts maintain a Buy rating amid mixed Q3 earnings results and major stock sales.
Headquartered in California, A-Mark Precious Metals, Inc. (NASDAQ:AMRK) is a fully integrated precious metals trading company. It is active in wholesale, secured lending, and direct-to-consumer channels. Founded in 1965, the company has distributed bullion and coins from sovereign and private mints in addition to offering storage and logistics services. It also provided financing solutions to dealers, investors, and industrial users globally.
The Q3 earnings call, released on May 7, 2025, revealed mixed results. The revenue for the quarter reached $3 billion, a 15% increase compared to the same quarter the previous year. A-Mark Precious Metals, Inc. (NASDAQ:AMRK) was also successful in acquiring Pinehurst Coin Exchange, Spectrum Group International, and AMS Holdings LLC. However, the net loss during the quarter reached $8.5 million, surpassing the $5 million net loss in the same quarter last year, due to trading losses and higher interest expenses.
On June 4, 2025, the company’s CFO, Kathleen Taylor-Simpson, made a bold move, selling 5,000 shares of the company in a transaction valued at $103,400. Even so, the company’s Buy rating by Maxim Group stood sturdily with a price target of $63, pouring confidence into the stock’s future performance.
A-Mark Precious Metals, Inc. (NASDAQ:AMRK) anticipates an EPS growth of 3.40% in the next five years, while maintaining a beta of 0.15, suggesting a blend of long-term growth and low risk.
10. Chemed Corporation (NYSE:CHE)
EPS next 5Y: 5.86%
Beta: 0.47
Chemed Corporation (NYSE:CHE) has earned a spot in our list of 11 best long term low risk stocks to buy. Analysts are dropping the price target on the stock after the company lowered its earnings guidance for 2025.
Ohio-based company, Chemed Corporation (NYSE:CHE) operates two main subsidiaries, VITAS Healthcare and Roto-Rooter. VITAS provides hospice and palliative care, while Roto-Rooter offers plumbing, drain cleaning, and water restoration services. With these distinct healthcare and essential home services platforms, the company serves both residential and commercial markets across the U.S.
On June 27, 2025, Chemed Corporation (NYSE:CHE) announced that it has lowered its full-year earnings guidance for 2025, as it expects lower earnings for the second quarter. The revenue for the first quarter stood at $646.9 million, a 9.8% year-on-year growth.
Following the announcement, Bank of America lowered its price target on the stock from $708 to $650 but maintains the Buy rating on the shares. RBC capital reflected the sentiment and reduced the price target accordingly, from $674 to $640, while keeping an Outperform rating.
Trading at $453.65 as of July 23, 2025, Chemed Corporation (NYSE:CHE)’s beta of 0.47 signals low volatility, while its EPS of 5.86% for the next 5 years indicates moderate but long term growth for interested investors.
9. The Coca-Cola Company (NYSE:KO)
EPS next 5Y: 6.24%
Beta: 0.44
The Coca-Cola Company (NYSE:KO) finds its way among our list of 11 best long term low risk stocks to buy. The company confirms adding a new soda following a push from the U.S. President and a resilient Q2 earnings.
The Coca-Cola Company (NYSE:KO) is a global total beverage firm offering over 200 brands across a wide range of beverages, including sparkling drinks, water, tea, coffee, and juices. Headquartered in Georgia, the company’s portfolio is comprised of products available in more than 200 countries through an extensive network of bottling partners and distributors. It sells approximately 2.2 billion servings of beverages every day.
President Donald Trump has been pushing The Coca-Cola Company (NYSE:KO) to include U.S.-grown cane sugar beverages in its lineup. And in its Q2 earnings call released on July 22, 2025, the company officially announced adding a new soda made with American-grown cane sugar to its product portfolio. The move marks a historic shift in the company’s sweetener strategy in the U.S.
In the Q2 earnings report, the company also highlighted a 1% growth in revenue despite a 1% decline in global unit case volume. James Quincey, Chairman and CEO, has made the following statement.
“Amid a shifting external landscape in the second quarter, the ability of our system to stay both focused and flexible enabled us to stay on course in the first half of the year”
With a low beta of 0.44, suggesting a strong resilience against market changes, The Coca-Cola Company (NYSE:KO) expects a 6.24% 5-year EPS growth, thus earning its place in our list of best long term low risk stocks.
8. Lantheus Holdings, Inc. (NASDAQ:LNTH)
EPS next 5Y: 8.36%
Beta: 0.15
Lantheus Holdings, Inc. (NASDAQ:LNTH) has earned a rank in our list of 11 best long term low risk stocks to buy. The company completes the acquisition of Life Molecular Imaging Limited amid a fall in the monthly and weekly performance of shares.
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Massachusetts-based company specializing in radiopharmaceuticals and diagnostic imaging. Through Lantheus Medical Imaging, Progenics, and EXINI, the company develops and commercializes precision diagnostics and radiotherapeutics used in oncology and cardiology. It is supported by strategic partnerships from global healthcare leaders.
On July 21, 2025, Lantheus Holdings, Inc. (NASDAQ:LNTH) announced the completion of the acquisition of Life Molecular Imaging Limited. With the $350 million acquisition and the addition of Neuraceq, an F-18 PET imaging agent, Lantheus Holdings, Inc. (NASDAQ:LNTH) increases its capabilities in Alzheimer’s disease diagnostics.
On the other hand, the company’s weekly and monthly performance were down by 10.98% and 8.65%, respectively. These declines follow the expiration of the company’s transitional pass-through payment status for its product PYLARIFY and the subsequent implementation of the mean unit cost pricing for Medicare fee-for-service coverage.
However, analysts, including Truist Financial and TD Cowen, stick to their Buy rating on the stock, signaling confidence in the company’s future growth.
Lantheus Holdings, Inc. (NASDAQ:LNTH) is anticipated to incur an 8.36% EPS growth in the next 5 years, and it currently has a low beta of 0.15, which makes the stock a good buy for investors seeking long term stocks with low risks.
7. Haemonetics Corporation (NYSE:HAE)
EPS next 5Y: 11.12%
Beta: 0.40
Haemonetics Corporation (NYSE:HAE) is included in our list of 11 best long term low risk stocks to buy. The company’s stocks are upgraded to Buy despite a 9% decline in revenue, reported in the Q4 earnings call.
Headquartered in Massachusetts, Haemonetics Corporation (NYSE:HAE) is engaged in the development and supply of innovative medical technologies and systems for blood and plasma collection, surgical cell salvage, and hospital transfusion services. The company has a global reach with business operations in more than 50 countries. Its integrated solutions help improve procedural efficiency and patient care within leading hospitals.
On May 8, 2025, Haemonetics Corporation (NYSE:HAE) released its Q4 2025 earnings report, which highlighted a 9% decline in revenue for the quarter and a 6% decline in fiscal 2025 due to the planned CSL transition. The revenue from the Blood Center in particular went down by 22%, while it is anticipated to decline by 23 to 26% in fiscal 2026 due to portfolio streaming.
Following these results, Citi maintained a Hold rating on the stock with a price target of $71 on May 22, 2025. Later, on July 9, 2025, the company upgraded the stock from Hold to Buy rating and raised the price target to $90, reflecting faith in the company’s growth potential.
Haemonetics (NYSE:HAE) offers strong stability with a low beta of 0.40 and promising growth potential, projecting an 11.12% EPS increase over the next five years.
6. United Bancorp, Inc. (NASDAQ:UBCP)
EPS next 5Y: 12.33%
Beta: 0.41
United Bancorp, Inc. (NASDAQ:UBCP) features in our list of 11 best long term low risk stocks to buy. The company’s shares saw a decline in the last month following major stock moves by the top executives.
Based in Ohio, United Bancorp, Inc. (NASDAQ:UBCP) is the bank holding company for Unified Bank. The company offers both commercial and retail banking services, including commercial, real estate, consumer loans, and deposit accounts. Its operations span eastern Ohio and northern West Virginia. Founded in 1902, the company serves local communities from a full-service branch and a loan production office.
During May 2025, United Bancorp, Inc. (NASDAQ:UBCP)’s top executives engaged in major purchases. The company’s Chair of the Board, President & CEO, Scott Everson, purchased 2,197 shares in a transaction valued at $29,923.
Director Gary Glessner also acquired 3,497 shares valued at $47,629. SVP CFO Randall Greenwood purchased 1,006 shares priced at a total of $13,701. Director Bethany E Schunn made a purchase as well, for 836 shares valued at $11,386. Director Brian M Hendershot made another significant purchase, acquiring 2,207 shares valued at $30,059. And finally, Director John Hoopingarner acquired 927 shares for $12,625.
These insider transactions suggest high confidence in the company’s future growth. However, the monthly performance of the stock faced a slight decline, and the stock was available at $13.75 per share as of July 22, 2025.
The stock still stands ideal for conservative long‑term investors seeking risk‑aware portfolio expansion as it combines steady stability with low beta 0.41 and solid projections, forecasting 12.33% EPS growth over five years.
5. Genie Energy Ltd. (NYSE:GNE)
EPS next 5Y: 16.29%
Beta: 0.15
Genie Energy Ltd. (NYSE:GNE) appears on our list of 11 best long term low risk stocks to buy. Following strong Q1 2025 earnings results, the company’s top executives made a significant stock sale.
Genie Energy Ltd. (NYSE:GNE) is a diversified energy holding company with operations in retail electricity and natural gas supply, renewable solar solutions, and oil & gas exploration. Headquartered in New Jersey, the company operates through its subsidiaries, including Genie Retail Energy and Genie Renewables, and focuses on clean-energy services in deregulated U.S. markets. The company combines traditional energy supply with forward-looking solar projects to capture markets.
On May 6, 2025, Genie Energy Ltd. (NYSE:GNE) announced its Q1 2025 earnings results. Based on the report, the company ended the quarter with approximately 413,000 meters of service after having reached a year-over-year increase of over 48,000 net new meters. Owing to this growth and a stable commodity pricing environment, the company has achieved an 18% year-over-year increase in its revenue and income from operations.
Despite the strong quarter results, the company’s Director Allan Sass sold 2,920 of the company’s shares in a total transaction valued at $51,742.
Yet the significantly low volatility with a beta of 0.15 alongside a projected EPS growth of 16.29% over five years suggests growth potential with reduced downside exposure, increasing the stock’s appeal.
4. Stride, Inc. (NYSE:LRN)
EPS next 5Y: 22.08%
Beta: 0.11
Stride, Inc. (NYSE:LRN) ranks among our list of 11 best long term low risk stocks to buy. The company’s shares are currently trading at a low price following the contract termination by Gallup-McKinley County Schools.
Stride, Inc. (NYSE:LRN) is an education technology and services company. Based in Virginia, the company operates fully remotely and offers K–12 curriculum, software, and career learning programs primarily online. The company serves both K–12 and adult learners through proprietary and third-party content and learning platforms, placing importance on lifelong education.
Gallup-McKinley County Schools announced on May 17, 2025, that it has terminated the contract with Stride, Inc. (NYSE:LRN), effective June 30, 2025. The School Board President, Christopher Mortensen, made the following statement during the announcement.
“We are taking this step to protect our students, uphold academic standards, and meet our obligations under state and federal law.”
Following the termination, the company’s share price tumbled. As of July 22, 2025, Stride, Inc. (NYSE:LRN)’s one-month performance has declined by 11.06% reaching $129.74. Meanwhile, CNN indicates an analyst consensus rating of Buy on the stock and a 1-year median price target of $165.00, suggesting confidence in the company’s growth potential.
Despite this contract loss, Stride, Inc. (NYSE:LRN) remains a low volatility pick with a 0.11 beta and 22.08% EPS growth forecast, with a strong long-term upside.
3. Electromed, Inc. (NYSE:ELMD)
EPS next 5Y: 23.66%
Beta: 0.39
Electromed, Inc. (NYSE:ELMD) earns a rank in our list of 11 best long term low risk stocks to buy. Analysts maintain a Buy rating stock amid strong Q3 earnings and the company’s inclusion in the Russell 2000 and Russell 3000 Indexes.
Minnesota-based company, Electromed, Inc. (NYSE:ELMD), develops, manufactures, and markets the SmartVest System, a high‑frequency chest wall oscillation device for airway clearance therapy. Bypassing traditional equipment channels, it operates via a direct‑to‑patient and provider model. The company serves patients with pulmonary conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders, in both home and acute care settings.
The Q3 earnings report released on May 13, 2025, indicated the 10th consecutive quarter of year-over-year revenue and net income growth. The company has achieved a year-over-year increase in revenue of 13.1% and a net income growth of 26.7%. Later, on May 27, 2025, the company announced that it will join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on June 27, 2025.
Following these announcements, Freedom Capital Markets initiated coverage of the stock with a Buy rating and a price target of $29. Electromed, Inc. (NYSE:ELMD) maintains the same rating and price target at Roth Capital as well.
Now part of the Russell 2000 and Russell 3000 Indexes, the company sustains an anticipated 5-year EPS growth of 23.66% while keeping the volatility in check with a low beta of 0.39.
2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
EPS next 5Y: 33.73%
Beta: 0.25
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) secures a spot on our list of 11 best long term low risk stocks to buy. Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders. Operating from its headquarters in California, the company gained U.S. approval for valbenazine (Ingrezza®) for tardive dyskinesia and markets treatments for Huntington’s chorea, adrenal hyperplasia, endometriosis, and uterine fibroids. The company’s comprehensive pipeline includes treatments for Parkinson’s, Tourette’s, and novel agents like NBI‑1117568 in schizophrenia trials.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the termination of its Phase 2 study on NBI-921352, an investigational drug, as of July 14, 2025. The company, with its tests, aimed to evaluate the safety and tolerability of the drug when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder. Phase 2 of the study involved assessing the drug’s ability to reduce seizure frequency in patients with SCN8A-DEE. As it failed to show a meaningful reduction, the study was terminated.
The company’s lead candidates continue to be crinecerfont for congenital adrenal hyperplasia (CAH), and NBI-1117568, a potential treatment for psychosis and cognitive disorders. Later, on July 21, 2025, Truist initiated coverage of the stock with a Buy rating and a price target of $163. On the other hand, Morgan Stanley, while maintaining the Buy rating, has raised the price target from $148 to $150.
Despite the trial setback, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) continues to show strong growth prospects with a 33.73% projected EPS increase and a low beta of 0.25.
1. Corcept Therapeutics Incorporated (NASDAQ:CORT)
EPS next 5Y: 69.48%
Beta: 0.20
Corcept Therapeutics Incorporated (NASDAQ:CORT) has made it into our list of the best long term low risk stocks to buy. The company completes a key drug study and has submitted a new drug application to the U.S. FDA.
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through glucocorticoid receptor antagonists. The company’s flagship drug, Korlym®, treats Cushing’s syndrome and features a growing pipeline of over 30 clinical-stage compounds targeting endocrinology, oncology, metabolism, and neurology.
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced the completion of its Phase 1 study involving the examination of the effects of itraconazole on the pharmacokinetics and safety of dazucorilant in healthy adults. The trial involved single-dose dazucorilant and repeated itraconazole doses. The study ran from May 31, 2024, to June 29, 2025, and is now concluded. The findings are expected to optimize drug interaction safety.
Additionally, after gaining positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies, Corcept Therapeutics Incorporated (NASDAQ:CORT) has submitted a new drug application to the U.S. FDA for relacorilant. The data from the earlier studies indicated that relacorilant combined with nab-paclitaxel highly improves progression-free and overall survival compared to nab-paclitaxel alone.
Analysts, including Piper Sandler and H.C. Wainwright, are maintaining their Buy rating on the stock, with a price target of $131 and $145, respectively.
In addition to the rating, Corcept Therapeutics Incorporated (NASDAQ:CORT) increases its appeal by offering a rare low-risk, high-growth appeal, with a beta of 0.20 and projected EPS growth of 69.48%.
While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 13 Best Low Risk High Growth Stocks to Buy.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
